MannKind: Afrezza Sales Still Having Trouble With Traction Dec. 18, 2016 5:18 PM ET Spencer Osborne •Sales remain under 300 scripts per week. •Refill traction remains critical issue. •Poor Sales, NASDAQ listing, and Cash remain top concerns. http://seekingalpha.com/article/4031266-mannkind-afrezza-sales-still-trouble-traction?app=1&auth_param=1vat:1c5e2pr:39e5e0f31cfcc1e8edb97044c11014c7&uprof=51